Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vectura receives milestone payment from Boehringer Ingleheim

This article was originally published in Scrip

Executive Summary

Vecturais to receive another €7.5 million milestone payment from Boehringer Ingelheimas part of the two companies' asthma and COPD deal. Vectura, which has been developing a multi-dose dry powder inhaler to deliver Boehringer Ingelheim's respiratory disease products, previously received licensing and milestone payments of €20 million and a €10 million equity investment from the German company. Though no details on what the milestone was connected to were released, Piper Jaffray analysts speculated that it was triggered by progress in the development of a drug/ device combination. The analysts added that the milestone is another sign that the collaboration is progressing well and that it should aid negotiations between Vectura and third parties that the company may wish to license its products to. Vectura could receive further milestones that could be up to €20 million for each drug that is approved, Piper Jaffray said. The UK company will also receive royalties on global sales of Boehringer Ingelheim products delivered using the inhaler.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts